Mmp2 as a predictive biomarker of response to antiangiogenic therapy and survival after therapy in cancer patients
AssigneesUniversite D'Aix-Marseille, Assistance Publique - Hopitaux De Marseille
InventorsOlivier Chinot, Emeline Tabouret
Life of this patent
Estimating the term…
Abstract
The present invention relates to the use of matrix metalloproteinase-2 (MMP2) as a predictive biomarker of response to antiangiogenic therapy and survival after antiangiogenic therapy in cancer patients, and to related methods for predicting or monitoring the response to an antiangiogenic treatment and the survival after said treatment of a cancer patient.
Claims15
Use of matrix metalloproteinase-2 (MMP2) as a predictive biomarker of response to antiangiogenic therapy and survival after antiangiogenic therapy in cancer patients.
A method for predicting the response to an antiangiogenic treatment and the survival after treatment of a cancer patient, which comprises the step of:
- measuring the level of MMP2 prior to said antiangiogenic treatment, in a biological sample from said patient, wherein a higher level of MMP2 in said sample, compared to a reference value, is indicative of a response to said antiangiogenic treatment and survival after treatment of said patient.
A method for monitoring the response to an antiangiogenic treatment of a patient suffering from cancer, comprising:
- measuring the level of MMP2 in a biological sample from the patient, at two or more time points during said antiangiogenic treatment, wherein an equal or higher level of MMP2 in said sample at a later time point, compared to a reference value obtained at an earlier time point, is indicative of a prolonged response to said antiangiogenic treatment, whereas a lower level of MMP2 is indicative of a resistance to said antiangiogenic therapy.
Dependencies are inferred from the claim text.